Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MIRATI THERAPEUTICS, INC.

(MRTX)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/12/2022 01/13/2022 01/14/2022 01/18/2022 01/19/2022 Date
122.56(c) 118.74(c) 124.31(c) 115.98(c) 120.81 Last
366 431 607 067 875 940 784 927 761 791 Volume
-3.71% -3.12% +4.69% -6.70% +4.16% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 67,9 M - -
Net income 2021 -544 M - -
Net cash position 2021 710 M - -
P/E ratio 2021 -11,4x
Yield 2021 -
Sales 2022 64,6 M - -
Net income 2022 -639 M - -
Net cash position 2022 535 M - -
P/E ratio 2022 -9,95x
Yield 2022 -
Capitalization 6 671 M 6 671 M -
EV / Sales 2021 87,7x
EV / Sales 2022 95,0x
Nbr of Employees -
Free-Float 92,8%
More Financials
Company
Mirati Therapeutics, Inc. is a clinical-stage oncology company. It is focused on developing therapeutics to address the genetic and immunological promoters of cancer. Its clinical programs consist of product candidates, including Adagrasib (MRTX849), MRTX1133, and Sitravatinib. MRTX849 is an oral small-molecule therapy designed to shrink difficult-to-treat cancers harboring the KRAS G12C mutation. MRTX1133 is a... 
More about the company
Ratings of Mirati Therapeutics, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C
More Ratings
All news about MIRATI THERAPEUTICS, INC.
01/10MIRATI THERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (f..
AQ
01/10Certain Common Stock of Mirati Therapeutics, Inc. are subject to a Lock-Up Agreement E..
CI
01/10Certain Restricted Stock Units of Mirati Therapeutics, Inc. are subject to a Lock-Up Ag..
CI
01/10Certain Pre-Funded Warrants of Mirati Therapeutics, Inc. are subject to a Lock-Up Agre..
CI
01/10Certain Common Stock of Mirati Therapeutics, Inc. are subject to a Lock-Up Agreement E..
CI
01/10Certain Restricted Stock Units of Mirati Therapeutics, Inc. are subject to a Lock-Up Ag..
CI
01/10Certain Pre-Funded Warrants of Mirati Therapeutics, Inc. are subject to a Lock-Up Agre..
CI
01/06INSIDER SELL : Mirati Therapeutics
MT
01/04Mirati Therapeutics to Present at the J.P. Morgan 40th Annual Virtual Healthcare Confer..
PR
2021Mirati Therapeutics to Participate in the 4th Annual Evercore ISI HealthCONx Conference
PR
2021Mirati Therapeutics and Verastem Oncology Partner to Evaluate Adagrasib in Combination ..
BU
2021BMO Capital Starts Mirati Therapeutics at Outperform With $187 Price Target
MT
2021Mirati Therapeutics Submits Investigational New-Drug Application to FDA for MRTX1719 to..
MT
2021Mirati Therapeutics Announces Submission of Investigational New Drug Application to U.S..
PR
2021Mirati Therapeutics, Inc. Announces Submission of Investigational New Drug Application ..
CI
More news
News in other languages on MIRATI THERAPEUTICS, INC.
2021Mirati Therapeutics soumet à la FDA une demande d'autorisation de mise sur le marché de..
2021Mirati Therapeutics réduit sa perte au troisième trimestre et augmente son chiffre d'af..
2021Earnings Flash (MRTX) MIRATI THERAPEUTICS affiche un chiffre d'affaires de 71,8 million..
2021Les actions du secteur de la santé se redressent tardivement et finissent juste en dess..
2021Les actions du secteur de la santé en légère baisse pour commencer la nouvelle semaine
More news
Analyst Recommendations on MIRATI THERAPEUTICS, INC.
More recommendations
Chart MIRATI THERAPEUTICS, INC.
Duration : Period :
Mirati Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MIRATI THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 15
Last Close Price 120,81 $
Average target price 212,82 $
Spread / Average Target 76,2%
EPS Revisions
Managers and Directors
David D. Meek Chief Executive Officer & Director
Charles M. Baum President, Director & Head-Research & Development
Vickie S. Reed Chief Financial & Accounting Officer
Faheem Hasnain Chairman
James G. Christensen Chief Scientific Officer & Executive VP
Sector and Competitors
1st jan.Capi. (M$)
MIRATI THERAPEUTICS, INC.-20.94%6 404
GILEAD SCIENCES, INC.-3.00%88 346
REGENERON PHARMACEUTICALS-3.21%63 906
VERTEX PHARMACEUTICALS5.22%58 750
WUXI APPTEC CO., LTD.-5.55%54 178
BIONTECH SE-34.36%40 873